Y mAbs Therapeutics (YMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Y mAbs Therapeutics (YMAB) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.65 Million) by net assets ($87.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Y mAbs Therapeutics for the company's overall valuation and market capitalisation.
Y mAbs Therapeutics - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Y mAbs Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Y mAbs Therapeutics ranked by their cash flow conversion efficiency. Explore YMAB cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
-0.006x |
|
GDI Integrated
TO:GDI
|
0.066x |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
-0.029x |
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
-0.096x |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
0.041x |
|
Unifique Telecomunicações S.A.
SA:FIQE3
|
0.145x |
|
Duratec Ltd
AU:DUR
|
0.215x |
|
Hamborner REIT AG
XETRA:HABA
|
0.031x |
Annual Cash Flow Conversion Efficiency for Y mAbs Therapeutics (2016–2024)
The table below shows the annual cash flow conversion efficiency of Y mAbs Therapeutics from 2016 to 2024. View Y mAbs Therapeutics share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.00 Million | $-15.71 Million | -0.171x | +36.66% |
| 2023-12-31 | $100.98 Million | $-27.23 Million | -0.270x | +61.21% |
| 2022-12-31 | $109.22 Million | $-75.92 Million | -0.695x | -22.07% |
| 2021-12-31 | $180.11 Million | $-102.56 Million | -0.569x | +33.94% |
| 2020-12-31 | $105.84 Million | $-91.23 Million | -0.862x | -133.28% |
| 2019-12-31 | $198.90 Million | $-73.50 Million | -0.370x | -25.95% |
| 2018-12-31 | $140.53 Million | $-41.23 Million | -0.293x | -51.87% |
| 2017-12-31 | $82.15 Million | $-15.87 Million | -0.193x | +79.13% |
| 2016-12-31 | $12.06 Million | $-11.17 Million | -0.926x | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more